TP53BP1 and digestive system neuroendocrine neoplasm: Consistent with findings of that study investigating DDR-markers in patients with gastroenteropancreatic neuroendocrine neoplasms treated with somatostatin receptor-targeted peptide receptor radionuclide therapy (PRRT), low levels of 53BP1 foci were linked to shorter PFS [22], supporting the notion of an incremental value of those DDR-markers for patients scheduled for endoradiotherapy.